Tirzepatide and the Kidney: Albuminuria, eGFR and Kidney Events From SURPASS-4 to SURPASS-CVOT

RESEARCH · TIRZEPATIDE · KIDNEY OUTCOMES

Tirzepatide and the Kidney: Albuminuria, eGFR and Kidney Events From SURPASS-4 to SURPASS-CVOT

PurixLab’s Tirzepatide 10mg is a research vial of the dual GIP/GLP-1 receptor agonist. Our earlier articles cover the SURPASS and SURMOUNT programme, body composition, liver fat and heart failure, receptor pharmacology and obstructive sleep apnoea. This article examines the kidney: albuminuria, estimated glomerular filtration rate (eGFR) and composite kidney outcomes in clinical trials, the measurement problems that complicate them, and the small preclinical and safety literature. These are published findings about the drug under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

The two kidney measures used in trials

Nearly every analysis below rests on two laboratory markers. The urine albumin-to-creatinine ratio (UACR) indexes albumin leakage, and eGFR estimates filtration from a blood marker, usually creatinine, sometimes cystatin C. Both have limits in people losing weight. Creatinine comes from muscle, so a change in muscle mass can move creatinine-based eGFR without any change in true filtration; cystatin C-based eGFR is described as unaffected by muscle mass changes [1]. In obesity, however, the synthesis of both markers can be influenced by fat and muscle mass and by changes in body composition [2]. None of the studies below measured GFR directly.

SURPASS-4: the first signal

SURPASS-4 randomised people with type 2 diabetes and high cardiovascular risk to tirzepatide or titrated insulin glargine; it was not designed as a kidney trial, and the kidney results come from a post-hoc analysis. Of 2002 participants randomly assigned, mean baseline eGFR was 81·3 mL/min per 1·73 m2 and median UACR 15·0 mg/g. The mean rate of eGFR decline was -1·4 mL/min per 1·73 m2 per year with pooled tirzepatide groups versus -3·6 with insulin glargine. UACR rose by 36·9% with glargine but not with tirzepatide, and a composite kidney outcome occurred less often with tirzepatide (hazard ratio 0·58) [3].

Because weight loss could distort creatinine, the same investigators then compared both estimating equations at 52 weeks. The between-group difference favoured tirzepatide by 1.4 mL/min/1.73 m2 with creatinine and 1.8 with cystatin C, and eGFR changes did not correlate with body weight changes [1]. The comparator matters: insulin glargine is not known for kidney effects beyond glucose lowering, so these results compare tirzepatide with a glucose-lowering therapy rather than with another incretin.

Pooled SURPASS and SURMOUNT analyses

Across SURPASS-1 to 5, a pooled post hoc analysis found adjusted UACR reductions versus all comparators of -19.3%, -22.0% and -26.3% at week 40/42 for the three tirzepatide strengths studied, with larger reductions in people with UACR of 30 mg/g or more. Mediation analysis suggested that approximately one-half of the albuminuria reduction may be related to weight loss, and there was no difference in eGFR at that time point [4].

In people without diabetes, a post hoc analysis of SURMOUNT-1 (N=2539) and SURMOUNT-2 (N=938) found median baseline UACR of 6.0 and 13.0 mg/g, so most participants had normal albumin excretion. The placebo-adjusted UACR difference at week 72 was −8.4% in SURMOUNT-1 and −31.1% in SURMOUNT-2, and larger in participants starting at 30 mg/g or more. Cystatin C-based eGFR rose by 3.2 mL/min per 1.73 m2 versus placebo in SURMOUNT-1, whereas in SURMOUNT-2 both groups rose with no between-group difference [5].

SURPASS-CVOT: an active comparator and hard events

The largest data set comes from SURPASS-CVOT, a double-blind trial in people with type 2 diabetes and atherosclerotic cardiovascular disease that compared tirzepatide with the GLP-1 receptor agonist dulaglutide. In a pre-specified exploratory analysis of 6586 participants assigned to tirzepatide and 6579 to dulaglutide, followed for a median of 4·0 years, the composite of persistent macroalbuminuria, a sustained eGFR fall of 50% or more, end-stage kidney disease or kidney death occurred in 6·0% versus 7·6% (hazard ratio 0·77). The effect in lower-risk chronic kidney disease was driven mainly by less new macroalbuminuria, and in high-risk chronic kidney disease by slower eGFR decline; nausea, vomiting and diarrhoea were more common with tirzepatide [6]. Because the comparator was itself an incretin drug, this is the most informative comparison so far, but the analysis was exploratory.

Heart failure, chronic kidney disease and discordant eGFR

The SUMMIT trial randomised 731 patients with heart failure with preserved ejection fraction and obesity, enriched for chronic kidney disease. Baseline cystatin C-based eGFR was consistently about 9 mL/min/1.73 m2 lower than creatinine-based eGFR. Tirzepatide lowered creatinine-based eGFR at 12 weeks, but not cystatin C-based eGFR, and both measures were higher at 52 weeks, with considerable discordance in individual patients [2].

Pharmacokinetics in renal impairment

A phase I study compared a single administration in 45 subjects ranging from normal renal function to end-stage renal disease on dialysis. Tirzepatide exposure was similar across groups, except for a 25-29% increase in AUCs in the moderate impairment group, and there was no significant relationship between exposure and eGFR [7]. This suggests that kidney function is not a major determinant of exposure, although the study did not address effects of the drug on the kidney.

Preclinical models and safety reports

Animal work is limited. In db/db mice, a model of diabetic kidney disease, tirzepatide improved glucose control and kidney measures more than liraglutide, while the triple agonist retatrutide was the most effective on kidney measures and weight [8]. In non-diabetic renal fibrosis, using unilateral ureteral obstruction and aged mice, tirzepatide effects were associated with PI3K-AKT inhibition and PPAR pathway activation; the authors present the work as hypothesis-generating [9]. On the safety side, a 2026 case report described biopsy-proven chronic active tubulointerstitial nephritis in a man with type 2 diabetes and stage 3b chronic kidney disease, with eGFR falling from 68 to 34 mL/min/1.73 m2 over 8 months and partial recovery after the drug was stopped and prednisone started [10]. A single case cannot establish frequency or causality.

Reading this literature critically

  • Study design. Most kidney results are post hoc or exploratory analyses of trials designed for glucose, weight or cardiovascular endpoints [3,4,6].
  • Weight. About half of the albuminuria effect may be weight-related [4], so separating direct kidney actions from weight loss remains difficult.
  • Measurement. Creatinine and cystatin C can diverge in obesity and during weight loss [2,1].
  • Sponsor. The SURPASS-4 and SURPASS-CVOT kidney analyses were funded by Eli Lilly and Company [3,6].

What remains open

  • Whether a dedicated kidney-outcome trial in chronic kidney disease, with measured GFR, confirms the exploratory signals.
  • How much of any effect is attributable to GIP receptor activity rather than GLP-1 receptor activity and weight loss.

Tirzepatide 10mg at PurixLab

Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tirzepatide 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Heerspink HJL, Sattar N, Pavo I, et al. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Diabetes Care. 2023;46(8):1501-1506. PubMed 37267479 · PMC10369133 · doi:10.2337/dc23-0261
  2. Packer M, Zile MR, Kramer CM, et al. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. J Am Coll Cardiol. 2025;85(18):1721-1735. PubMed 40162940 · doi:10.1016/j.jacc.2025.03.009
  3. Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774-785. PubMed 36152639 · doi:10.1016/S2213-8587(22)00243-1
  4. Apperloo EM, Tuttle KR, Pavo I, et al. Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials. Diabetes Care. 2025;48(3):430-436. PubMed 39746157 · PMC11870291 · doi:10.2337/dc24-1773
  5. Heerspink HJL, Friedman AN, Bjornstad P, et al. Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes. J Am Soc Nephrol. 2025;36(11):2190-2200. PubMed 40512543 · PMC12591676 · doi:10.1681/ASN.0000000764
  6. Zoungas S, D'Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol. 2026;14(7):544-557. PubMed 42114520 · doi:10.1016/S2213-8587(26)00032-X
  7. Urva S, Quinlan T, Landry J, et al. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2021;60(8):1049-1059. PubMed 33778934 · PMC8332596 · doi:10.1007/s40262-021-01012-2
  8. Ma J, Hu X, Zhang W, et al. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. PubMed 39212900 · doi:10.1007/s12020-024-03998-8
  9. Ding M, Li X, Wei Y, et al. Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. iScience. 2026;29(9):117174. PubMed 42630988 · PMC13495082 · doi:10.1016/j.isci.2026.117174
  10. Eldib M, Mendpara V, Herlitz L, et al. Tirzepatide-associated interstitial kidney injury. JCEM Case Rep. 2026;4(6):luag125. PubMed 42093865 · PMC13142148 · doi:10.1210/jcemcr/luag125

Leave a Comment

Your email address will not be published. Required fields are marked *